EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • September 20th, 2021 • Petra Acquisition Inc. • Blank checks • California
This Executive Employment Agreement (the “Agreement”) is entered into as of the Effective Date (as defined below) by and between Chester Zygmont, III (“Executive”), and Revelation Biosciences, Inc., a Delaware corporation (the ”Company”). The Company and Executive may hereinafter each individually be referred to as a “Party” and collectively as the “Parties,” as the context may require.
REVELATION BIOSCIENCES, INC. COMMON STOCK WARRANT January 31, 2021 Void After January 31, 2027Petra Acquisition Inc. • September 20th, 2021 • Blank checks • New York
THIS CERTIFIES THAT, for value received and subject to the terms and conditions set forth below, National Securities Corporation, or assigns (the “Holder”), is entitled to subscribe for and purchase at the Exercise Price (defined below) from Revelation Biosciences, Inc., a Delaware corporation (the “Company”), Sixty-One Thousand Six-Hundred (61,600) fully-paid and non-assessable shares of Common Stock of the Company. This Warrant is being issued pursuant to that certain Placement Agent Agreement by and between the National Securities Corporation and the Company, dated January 27, 2021 (the “Agreement”).
November 3, 2020 STRICTLY CONFIDENTIAL Petra Acquisition, Inc. New York, NY 10010 Attn: Andreas Typaldos Dear Mr. Typaldos:Letter Agreement • September 20th, 2021 • Petra Acquisition Inc. • Blank checks • New York
This letter agreement (the “Agreement”) will confirm the understanding and agreement between Petra Acquisition, Inc., a Delaware corporation, located at 5 West 21st Street, New York, NY 10010 (together with its subsidiaries and affiliates, collectively, the “Company”), and LifeSci Capital LLC (“LifeSci”) pursuant to which LifeSci shall provide investment banking and financial advisory services to the Company with respect to the Company’s efforts to engage in a Transaction with a Target (each, as defined below) as provided for herein. It is acknowledged and agreed that this Agreement shall be effective as of the date of mutual execution hereof (the “Effective Date”).
December 31, 2020 Revelation Biosciences, Inc. Re: Global Health Agreement Ladies and Gentlemen:Letter Agreement • September 20th, 2021 • Petra Acquisition Inc. • Blank checks • Delaware
This global health letter agreement (“Global Health Agreement”) is entered into by and between Revelation Biosciences, Inc. a Delaware corporation (the “Company”) and AXA Prime Impact Master Fund I SCA SICAV-RAIF (the “Investor” or “AXA IM Impact Fund”) in connection with its commitment to purchase certain shares of the Company’s Series A Preferred Stock (the “Shares”) in accordance with the terms of that certain Series A Preferred Stock Purchase Agreement dated as of even date herewith (the “Purchase Agreement”), at a price of $6.36 per share (for a total of $3,999,994.80) (the “Investment”).
Re: Amendment to Engagement Letter AgreementPetra Acquisition Inc. • September 20th, 2021 • Blank checks
This letter amends that certain engagement letter agreement dated November 3, 2020 (the “Agreement), by and between Petra Acquisition, Inc., a Delaware corporation (collectively, with its subsidiaries and affiliates, the “Company”) and LifeSci Capital LLC (“LifeSci”), attached hereto as “Exhibit A,” pursuant to which LifeSci agreed to provide certain investment banking and financial advisory services to the Company with respect to the Company’s efforts to engage in an initial business combination transaction. Capitalized terms used herein and not otherwise defined have the meetings ascribed to them in the Agreement.
